PolyPeptide Group AG (SWX:PPGN)

Market Cap	1.26B +90.1%
Revenue (ttm)	362.47M +15.6%
Net Income	-19.71M
EPS	-0.60
Shares Out	33.01M
PE Ratio	n/a
Forward PE	66.94
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,123
Open	38.45
Previous Close	38.30
Day's Range	37.70 - 38.45
52-Week Range	19.62 - 41.70
Beta	1.02
Analysts	Buy
Price Target	35.63 (-5.62%)
Earnings Date	Aug 13, 2026

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1952
• Employees: 1,440
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: PPGN

Financial Performance

In 2025, PolyPeptide Group AG's revenue was 389.33 million, an increase of 15.60% compared to the previous year's 336.79 million. Losses were -21.17 million, 8.20% more than in 2024.

Financial numbers in EUR

Analyst Summary

According to 6 analysts, the average rating for PPGN stock is "Buy." The 12-month stock price target is CHF 35.63, which is a decrease of -5.62% from the latest price.

Price Target

CHF 35.63

(-5.62% downside)

Analyst Consensus: Buy